FDA Clearance Tracker · P210005-S005
IC-8 Apthera Intraocular Lens
Last checked: Nov 20, 2026Latest source record: Jul 31, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jul 31, 2023
Approved
Time to decision
60 days
Received Jun 1, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P210005-S005
- Device name
- IC-8 Apthera Intraocular Lens
- Applicant
- Acu Focus, Inc.
- Applicant location
- Irvine, CA
- Received
- Jun 1, 2023
- Decided
- Jul 31, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P210005
Device type
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site located at Bausch & Lomb, 21 N. Park Place Blvd., Clearwater, Florida, 33759 for the following functions: 1) Receiving inspections of device raw materials/ subassemblies 2) Shipping and handling of device raw materials/subassemblies 3) Lot release and documentation review of finished devices 4) Handling, storage, preservation and distribution of finished devices.
Source documents
Other decisions for Acu Focus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P210005 · Decided Jul 22, 2022 · 513 days after receipt
Device type: Extended depth of focus intraocular lens (POE) · Ophthalmology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.